This is a preview of subscription content, log in via an institution to check access.
References
R.S. Douglas, G.J. Kahaly, A. Patel, S. Sile, E.H.Z. Thompson, R. Perdok et al. Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 382, 341–352 (2020)
K. Müller, D. Führer, J. Mittag, N. Klöting, M. Blüher, R.E. Weiss et al. TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia. Mol. Endocrinol. 25, 1867–1879 (2011)
C. A. Spencer. Assay of thyroid hormones and related substances. [Updated 2017 Feb 20]. in Endotext, ed. by K. R. Feingold, B. Anawalt, A. Boyce et al. (MDText.com, Inc., South Dartmouth, MA, 2000). https://www.ncbi.nlm.nih.gov/books/NBK279113/
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares no competing interests.
Ethics approval
This article does not contain any studies with human participants or animals performed by the author. Informed consent was obtained from the patient.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yu, R. Thyroid function suppression after initiation of teprotumumab treatment. Endocrine 73, 561–562 (2021). https://doi.org/10.1007/s12020-021-02676-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02676-3